SMCHD1

Across TCGA pan-cancer cohorts, SMCHD1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SMCHD1 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher SMCHD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMCHD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

MESO, LUSC, and UCEC are the cancer types where SMCHD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	IV	0.036	0.602	<.001	42	view →
LUSC	OS	Median	II,III,IV	0.236	0.749	<.001	41	view →
UCEC	DFS	Median	All	0.791	0.627	.002	20	view →
COAD	OS	Median	III,IV	0.140	0.792	<.001	15	view →
PAAD	OS	Median	All	0.112	0.640	.004	12	view →
SKCM	DFS	Median	III,IV	0.639	0.243	.032	4	view →
LIHC	OS	Median	All	0.486	0.777	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SMCHD1–MESO (OS)

Open the MESO breakdown →